Equillium Announces Poster Presentations at IMMUNOLOGY2026™

Biotech company to share new preclinical data on its AhR modulator EQ504 at annual immunology conference.

Apr. 8, 2026 at 12:58pm

Got story updates? Submit your updates here. ›

Equillium, Inc., a biotechnology company developing novel therapies for autoimmune and inflammatory disorders, announced that new preclinical data on its investigational drug EQ504 will be presented as posters at the upcoming IMMUNOLOGY2026™ annual meeting of the American Association of Immunologists in Boston. The data highlights EQ504's potential as a potent AhR modulator with the ability to promote immune tolerance and epithelial barrier restoration, which could be beneficial for treating conditions like ulcerative colitis.

Why it matters

As a selective AhR modulator, EQ504 represents a novel therapeutic approach that could address both the inflammatory and tissue repair aspects of autoimmune and inflammatory diseases. The upcoming poster presentations at a major immunology conference will provide important visibility for Equillium's pipeline and help generate interest from the scientific community.

The details

Equillium will present two posters on EQ504 at IMMUNOLOGY2026™. The first poster will focus on how EQ504 promotes immune tolerance through the release of the anti-inflammatory cytokines IL-10 and IL-22. The second poster will highlight EQ504's ability to enhance epithelial repair and barrier restoration compared to other clinically validated AhR agonists. Both presentations will take place in the exhibit hall, with the speakers available for Q&A during the designated time slots.

  • The IMMUNOLOGY2026™ conference will take place from April 15-19, 2026 in Boston, Massachusetts.
  • The first EQ504 poster presentation will be on Thursday, April 16, 2026 from 2:30 PM - 3:30 PM EDT.
  • The second EQ504 poster presentation will be on Saturday, April 18, 2026 from 11:30 AM - 12:30 PM EDT.

The players

Equillium, Inc.

A biotechnology company developing novel therapies to treat severe autoimmune and inflammatory disorders. Equillium's lead investigational drug is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator.

Dr. Stephen Connelly

Chief Scientific Officer of Equillium, who commented on the significance of the EQ504 preclinical data being presented.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to share these preclinical findings that support the differentiated profile of EQ504 as a potent AhR modulator, with the potential to influence both immune cell responses and barrier restoration.”

— Dr. Stephen Connelly, Chief Scientific Officer

What’s next

Following the poster presentations, the materials will be made available on Equillium's website for further review by the scientific community.

The takeaway

Equillium's development of EQ504, a novel AhR modulator, represents a promising approach to addressing both the inflammatory and tissue repair aspects of autoimmune and inflammatory diseases. The upcoming conference presentations will help raise awareness of this investigational therapy and its potential benefits.